Application of puerarin in muscular atrophy, myopathy and musculoskeletal complications

A muscle atrophy and puerarin technology, applied in the field of medicine, can solve the problem of no report on the direct or indirect therapeutic effect of puerarin, and achieve the effect of drug safety and reliability

Pending Publication Date: 2020-05-01
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the direct or indirect therapeutic effect of puerarin on muscle atrophy and improving muscle atrophy caused by metabolic diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of puerarin in muscular atrophy, myopathy and musculoskeletal complications
  • Application of puerarin in muscular atrophy, myopathy and musculoskeletal complications
  • Application of puerarin in muscular atrophy, myopathy and musculoskeletal complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1: The effect of puerarin on general conditions such as food intake / body weight / blood sugar / glycemic tolerance of type 1 diabetic rats

[0038] 1.1 Establishment of diabetic rat model and administration

[0039] Experimental principle

[0040] SD rats use streptozotocin (STZ) to induce type 1 diabetes, and diabetic complications can occur in the late stage.

[0041] experimental method

[0042] Male SD rats weighing 200-250g, after 1 week of adaptive feeding, intraperitoneal injection of 1.3g / 100ml streptozotocin (STZ) 65mg / kg, one week later, blood was collected from the tail, and the blood glucose level was measured with a Roche blood glucose meter . The rats with fasting blood glucose greater than 16.5mmol / L were selected as the type 1 diabetes rat model.

[0043] Twenty male SD rats with blood glucose≥16.5mmol / L were randomly divided into two groups, the diabetes control group and the 100mg / kg puerarin administration group. After grouping, intragastric administratio...

Embodiment 2

[0078] Example 2: The effect of puerarin on the contractility of skeletal muscle caused by diabetes

[0079] 2.1 Establishment of diabetic rat model and administration

[0080] The experimental principle, experimental method, and experimental results are the same as in Example 1.1.

[0081] 2.2 The effect of puerarin on the contractility of skeletal muscle caused by diabetes

[0082] Experimental principle

[0083] The purpose of testing animal skeletal muscle contractility is to evaluate the degree of influence of various factors on animal limb strength. It can also measure animal aging, nerve damage, bone damage, and muscle damage. The measurement method is simple to operate, easy to use, clear indicators, strong specificity, and can measure the real and objective grip of the animal.

[0084] experimental method

[0085] Animal grip: measure the grip of animal limbs. A gripping force meter is used to measure the grip level of the forelimbs. The grasping force tester is used to measur...

Embodiment 3

[0102] Example 3: The effect of puerarin on skeletal muscle weight caused by diabetes

[0103] 3.1 Establishment of diabetic rat model and administration situation

[0104] The experimental principle, experimental method, and experimental results are the same as in Example 1.1.

[0105] 3.2 The effect of puerarin on skeletal muscle weight caused by diabetes

[0106] experimental method

[0107] Animal skeletal muscle weight: Determine the absolute weight and weight index of gastrocnemius, soleus, and tibial anterior muscle. After the animal was executed, different parts of the organs were taken. Rinse with pre-cooled normal saline, and record the organ weight after qualitative filter paper absorbs the residual moisture. Take the muscles of the calf, separate the muscles precisely, and weigh them.

[0108] Experimental results

[0109] Compared with normal, the weight of gastrocnemius, Soleus, and Tibialis anterior of diabetic animals decreased significantly. After 8 weeks of administr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel pharmacological action of a traditional Chinese medicine monomer puerarin. The novel pharmacological action comprises prevention, relief and / or treatment of myopathy,muscular atrophy and musculoskeletal complications caused by metabolic diseases including diabetes, hyperlipidaemia, obesity and thyroid diseases. The puerarin has the following advantages: the puerarin has the effects of delaying and treating muscular atrophy caused by related metabolic diseases like diabetes, hyperlipidaemia, obesity and thyroid diseases; the puerarin has the pharmacological effects of increasing skeletal muscle strength, improving skeletal muscle tissue microcirculation, increasing skeletal muscle weight and improving skeletal muscle peripheral neuropathy; the puerarin is amonomeric compound extracted from kudzuvine root, is low in toxicity and wide in raw material resource, and has good application and development prospects; and the puerarin can be used for preventing, relieving and treating muscular atrophy, myopathy and musculoskeletal complications caused by related metabolic diseases like diabetes, hyperlipidaemia, obesity and thyroid diseases.

Description

Technical field [0001] The invention relates to the application of puerarin in the preparation of products for the prevention, alleviation and / or treatment of myopathy, muscle atrophy and musculoskeletal complications caused by diabetes, hyperlipidemia, obesity, thyroid disease and other related metabolic diseases, and belongs to medical technology field. Background technique [0002] Diabetes is a group of metabolic diseases characterized by increased blood glucose levels. The pathophysiological mechanism that causes the increase in blood sugar is the defect of insulin secretion and the defect of insulin action. In the diabetic state, skeletal muscles may have muscle weight loss, muscle weakness and atrophy (Lancet, 1953, 1(6768):968-9.). Muscle atrophy and dysfunction are one of the main complications of diabetes (Nat Rev Drug Discov, 2015, 14(1): 58-74). Diabetic myopathy can lead to extreme fatigue, severe patient quality of life and self-care ability (Acta Diabetol, 2016,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P21/00A61P19/08
CPCA61K31/352A61P21/00A61P19/08
Inventor 杜冠华杨秀颖殷琳强桂芬张莉陈熙贾伟华王诺琦
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap